Ann: PARADIGM CLEARED FOR PHASE 3 TRIAL BY US FDA, page-135

It doesn't really matter what the share price is in the short-term or whether short sellers intend to play games, since this is typical of biotech stocks on the ASX with a high Market Cap. What matters is the change in fundamentals represented by today's announcement, which includes:

1. PAR is now a phase 3 asset.
2. The downtrend has been broken and a new uptrend has commenced.
3. The IND has been validated by the FDA and can be used for any other disease PAR intends to treat using iPPS.
4. PAR can begin recruiting for clinical trials that will result in global registration (AU, EU and US) if the results are positive. We will know the results in 2 years time.
5. PAR can now shift their focus to other aspects of the business, so we can expect a lot of news flow and promotional work over of the coming months.
6. A re-rate

If the share price gets pushed down this represents only one thing: more value.